Alamar Biosciences
This article was originally published in The Gray Sheet
Executive Summary
Plans an offering of $2.3 mil. in units, each consisting of convertible preferred stock and common stock purchase warrants. Proceeds from the offering are slated for increased marketing efforts for the Sacramento, California-based company's in vitro diagnostic test kits